Market Overview:
The global bevacizumab injection market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of age-related macular degeneration (AMD) and ovarian cancer, and the rising demand for bevacizumab injection in emerging markets. Based on type, the global bevacizumab injection market is segmented into 100mg and 400mg segments. The 100mg segment is expected to account for a larger share of the market than the 400mg segment during the forecast period. This can be attributed to its lower cost as compared to other types of bevacizumab injections available in the market.S., Canada, Germany, France, Italy Spain Japan etc., and also due t o th e availability o f advanced treatment options for this disease such as anti-VEGF therapies including ranibizumab (Lucentis)andaflibercept(Eylea).
Product Definition:
Bevacizumab is a monoclonal antibody that blocks the action of vascular endothelial growth factor (VEGF). Bevacizumab injection is used to treat certain types of cancer, including colon and rectal cancer, lung cancer, glioblastoma (a type of brain tumor), and metastatic renal cell carcinoma (a type of kidney cancer).
100mg:
Bevacizumab is a humanized monoclonal antibody that targets and binds to thebevacizumab. It is used in the treatment of patients with metastatic breast cancer who have received chemotherapy or radiation therapy. The drug was approved byFDA for this indication in 2007 and it gained wide acceptance following its launch.
400mg:
400mg is used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and peripheral artery disease. It is also used as an off-label drug for the treatment of relapsing-remitting multiple sclerosis. 400 mg bevacizumab injection can also be used for treating patients with acute multi-organ failure due to poisoning or drug abuse, but it has not been approved by the FDA for this use.
Application Insights:
The others segment held the largest share of over 70.0% in 2017 owing to its high usage in various indications such as rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), Sjogren¢â‚¬â„¢s syndrome, and dry eye disease. The AMD segment is expected to be the fastest growing application with a CAGR of XX% from 2018 to 2030 due to increasing prevalence and awareness about early diagnosis & treatment options for this condition among individuals aged 50 years & above.
AMD is a leading cause of blindness among individuals aged 60 years & above and the second most common cause of visual impairment after cataract surgery blindness in individuals between 40-59 years old globally.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing R&D activities, rising healthcare expenditure, and growing adoption of modern treatment techniques for various diseases. Moreover, high prevalence of age-related macular degeneration (AMD) in U.S.
Asia Pacific bevacizumab injection market is anticipated to grow at a lucrative rate over the forecast period owing to factors such as improving healthcare infrastructure and economic development in emerging countries like China & India & South Korea etcetera).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the bevacizumab injection market. According to a study by the World Health Organization (WHO), it is estimated that there will be an increase in new cases of cancer from 14 million in 2012 to 22 million by 2030. This will create a high demand for bevacizumab injection as it is used for treatment of various types of cancers.
- Rising awareness about cancer and its treatments: There has been an increase in awareness about different types of cancers and their treatments over the past few years. This has led to an increased demand for bevacizumab injection as it is one of the most commonly used drugs for treating various types of cancers.
- Technological advancements in oncology therapies: The technological advancements in oncology therapies have led to better outcomes with fewer side effects, which has resulted in an increased demand for bevacizumab injection globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bevacizumab Injection Market Research Report
By Type
100mg, 400mg
By Application
Age-related macular degeneration (AMD), Ovarian Cancer, Others
By Companies
Pfizer, Roche, Eli Lilly, Genentech, Bayer, Amgen, Samsung Bioepis, Centus, Cadila Pharmaceuticals, Dr Reddy's, Pfizer, Hetero Group, Biocon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Bevacizumab Injection Market Report Segments:
The global Bevacizumab Injection market is segmented on the basis of:
Types
100mg, 400mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Age-related macular degeneration (AMD), Ovarian Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche
- Eli Lilly
- Genentech
- Bayer
- Amgen
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Pfizer
- Hetero Group
- Biocon
Highlights of The Bevacizumab Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg
- 400mg
- By Application:
- Age-related macular degeneration (AMD)
- Ovarian Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bevacizumab Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bevacizumab injection is a medication that is used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the bevacizumab injection market are Pfizer, Roche, Eli Lilly, Genentech, Bayer, Amgen, Samsung Bioepis, Centus, Cadila Pharmaceuticals, Dr Reddy's, Pfizer, Hetero Group, Biocon.
The bevacizumab injection market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bevacizumab Injection Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Bevacizumab Injection Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Bevacizumab Injection Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Bevacizumab Injection Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Bevacizumab Injection Market Size & Forecast, 2018-2028 4.5.1 Bevacizumab Injection Market Size and Y-o-Y Growth 4.5.2 Bevacizumab Injection Market Absolute $ Opportunity
Chapter 5 Global Bevacizumab Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bevacizumab Injection Market Size Forecast by Type
5.2.1 100mg
5.2.2 400mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bevacizumab Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bevacizumab Injection Market Size Forecast by Applications
6.2.1 Age-related macular degeneration (AMD)
6.2.2 Ovarian Cancer
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bevacizumab Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bevacizumab Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bevacizumab Injection Analysis and Forecast
9.1 Introduction
9.2 North America Bevacizumab Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bevacizumab Injection Market Size Forecast by Type
9.6.1 100mg
9.6.2 400mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bevacizumab Injection Market Size Forecast by Applications
9.10.1 Age-related macular degeneration (AMD)
9.10.2 Ovarian Cancer
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bevacizumab Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Bevacizumab Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bevacizumab Injection Market Size Forecast by Type
10.6.1 100mg
10.6.2 400mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bevacizumab Injection Market Size Forecast by Applications
10.10.1 Age-related macular degeneration (AMD)
10.10.2 Ovarian Cancer
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bevacizumab Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bevacizumab Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bevacizumab Injection Market Size Forecast by Type
11.6.1 100mg
11.6.2 400mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bevacizumab Injection Market Size Forecast by Applications
11.10.1 Age-related macular degeneration (AMD)
11.10.2 Ovarian Cancer
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bevacizumab Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Bevacizumab Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bevacizumab Injection Market Size Forecast by Type
12.6.1 100mg
12.6.2 400mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bevacizumab Injection Market Size Forecast by Applications
12.10.1 Age-related macular degeneration (AMD)
12.10.2 Ovarian Cancer
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bevacizumab Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bevacizumab Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bevacizumab Injection Market Size Forecast by Type
13.6.1 100mg
13.6.2 400mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bevacizumab Injection Market Size Forecast by Applications
13.10.1 Age-related macular degeneration (AMD)
13.10.2 Ovarian Cancer
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bevacizumab Injection Market: Competitive Dashboard
14.2 Global Bevacizumab Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche
14.3.3 Eli Lilly
14.3.4 Genentech
14.3.5 Bayer
14.3.6 Amgen
14.3.7 Samsung Bioepis
14.3.8 Centus
14.3.9 Cadila Pharmaceuticals
14.3.10 Dr Reddy's
14.3.11 Pfizer
14.3.12 Hetero Group
14.3.13 Biocon